1Kantarjian H,Cortes J,O'Brien S,et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon alpha [J]. Blood,2004,104:1979 - 1988. 被引量：1
2O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose eytarabine for newly diagnosed chronicphase chronic myeloid leukemia [ J ]. N Engl J Med, 2003,348 : 994 - 1004. 被引量：1
3Kantarjian H,Cortes J,O'Brien S,et al. Imatinib mesylate( STI571 ) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase[ J]. Blood,2002,99:3547 - 3553. 被引量：1
4Stephanie GW. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy [ J ]. Blood,2005, 106:2128 -2137. 被引量：1
5Cortes JE, Talpaz M,Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy[J]. Blood,2003,101:3794 -3800. 被引量：1
6Huntly BJ,Guilhot F,Reid AG,et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions [ J ]. Blood ,2003,102:2205 - 2212. 被引量：1
2Kim SH, Kim D, Kim DW,et al. Analysis of Bcr-Abl kinase domainmutations in Korean chronic myeloid leukaemia patients:poor clinical outcome of P-loop and T315I mutation is disease phase dependent [ J ]. Hematol Onco1,2009,27 (4) : 190-197. 被引量：1
3O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia:keeping resistance in check [ J ]. Expert Opin Investig Drugs,2008,17 ( 6 ) :865-878. 被引量：1
4Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformcd hematopoi- etic cell lines [ J ]. Blood, 2000,95 ( 11 ) : 3498-3505. 被引量：1
5homas J,Wang LH, Clak RE, et al. Active transport of imatinibinto and out of cells:implication for drug resistance [ J ]. Blood, 2004,104(12) :3739-3745. 被引量：1
6Holtz MS, Slovak ML, Zhang F, et al. Imatinib mesylate ( ST1571 ) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased prolif-eration[ J]. Blood ,2002,99 ( 10 ) :3792-3800. 被引量：1
7Fang BJ,Zheng CM,Liao LM,et al. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblaslic characteristics [ J ]. Blood, 2005,105 : 2733-2740. 被引量：1
8Wu J, Meng F, Lu H,et al. Lyn regulates BCR-ABL and Gab2 lyrosine phosphorylation and c-Cbl protein stability in imatinib-resist- ant chronic myelogenous leukemia cells [ J ]. Blood,2008,111 (7) : 3821-3829. 被引量：1
9Kantarjian HM,Talpaz M,O'brien S,et al. Dose escalation of irnatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia [ J ]. Blood, 2003,101 (2) :473-475. 被引量：1
10Le Coutre P, Ottmann OG, Giles F, et al. Nilolinib(formerlyAMN107), a high selective BCR-ABL tyrosine kinase inhibitor, is active in patients with iraatinib-resistant orintolerant accelerated phase chronic myelogenous leukemia [ J ]. Blood, 2008, 111(4) :1834-1839. 被引量：1
